Potential Anti 2019-nCoV Drug: Remdesivir

At present, the pneumonia caused by the novel coronavirus (2019-nCoV) infection has developed into a serious public health and safety problem. Currently, there is no targeted antiviral drugs for the virus. Remdesivir (GS-5734) is a new nucleotide analogue antiviral drug developed by Gilead science. The targeted clinical trials against 2019-CoV have been launched in China as remdesivir has shown a good effect in anti SARS-CoV and MERS-CoV. In this paper, the basic information, mechanism of action, pharmacokinetics, research status in domestic and international of remdesivir are summarized in order to provide reference for clinical medication.